𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Randomized trial or the selective aromatase inhibitor formestane (Lentaron®) versus tamoxifen as first-line hormonal therapy in postmenopausal patients with advanced breast cancer

✍ Scribed by R. Peréz-Carrion; V. Alberola; F. Calabresi; R-Th. Michel; R. Santos; M. Fehling; C.M. Royce; P.F. Trunet


Book ID
113404319
Publisher
Elsevier Science
Year
1993
Tongue
English
Weight
298 KB
Volume
2
Category
Article
ISSN
0960-9776

No coin nor oath required. For personal study only.


📜 SIMILAR VOLUMES